Precision medicine: In need of guidance and surveillance.

about

Precision medicine: In need of guidance and surveillance.

Item

http://www.wikidata.org/entity/Q42340386

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Precision medicine: In need of guidance and surveillance.

@en

Precision medicine: In need of guidance and surveillance.

@nl

type

Item

label

Precision medicine: In need of guidance and surveillance.

@en

Precision medicine: In need of guidance and surveillance.

@nl

prefLabel

Precision medicine: In need of guidance and surveillance.

@en

Precision medicine: In need of guidance and surveillance.

@nl

P1476

Precision medicine: In need of guidance and surveillance

@en

P2093

An-Qiang Wang

http://www.w3.org/2001/XMLSchema#string

Hai-Tao Zhao

http://www.w3.org/2001/XMLSchema#string

Jian-Zhen Lin

http://www.w3.org/2001/XMLSchema#string

Jun-Yu Long

http://www.w3.org/2001/XMLSchema#string

P2860

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Detection of circulating tumor DNA in early- and late-stage human malignancies

Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer

P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Identifying multiple causative genes at a single GWAS locus

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Biomarkers in Search of Precision Medicine in IBD.

P304

5045-5050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3748/WJG.V23.I28.5045

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ying Zheng

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28811702

http://www.w3.org/2001/XMLSchema#string

P932

5537174

http://www.w3.org/2001/XMLSchema#string